Fig 5. Therapeutic oral administration of BBG9-1 alleviates RV-induced loss of acidic mucin in the small intestine.

Oral administration of BBG9-1 and inoculation of RV were performed as described in the legend of Fig 2. Small intestines were harvested 2 days after infection. Paraffin-embedded sections were stained with HID/AB. (A) Upper and lower panels show HID/AB-stained sections of the jejunum and ileum, respectively. Scale bar represents 100 μm. HID-positive brown and AB-positive blue were defined as goblet cells containing sulfated mucins and sialomucins, respectively. (B)The number of goblet cells containing each mucin was calculated per length of villi, and the proportions of goblet cells containing sialomucins in the jejunum and ileum were calculated. Data are shown as means ± S.E. (n = 33–43 sections for each group). *p < 0.05 and **p<0.01 compared with the Non-RV group; ^##p<0.01 compared with the RV-Control group by the Tukey-Kramer test.